JP6730194B2 - アンドロゲン合成モジュレーター - Google Patents

アンドロゲン合成モジュレーター Download PDF

Info

Publication number
JP6730194B2
JP6730194B2 JP2016564185A JP2016564185A JP6730194B2 JP 6730194 B2 JP6730194 B2 JP 6730194B2 JP 2016564185 A JP2016564185 A JP 2016564185A JP 2016564185 A JP2016564185 A JP 2016564185A JP 6730194 B2 JP6730194 B2 JP 6730194B2
Authority
JP
Japan
Prior art keywords
day
acid
disclosed
conjugated
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016564185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514816A (ja
JP2017514816A5 (enExample
Inventor
ディリー，スザンヌ，ジェーン
ストロフ，グレゴリー，アラン
テイラー，ポール，クリストファー
Original Assignee
タンジェント リプロファイリング リミテッド
タンジェント リプロファイリング リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タンジェント リプロファイリング リミテッド, タンジェント リプロファイリング リミテッド filed Critical タンジェント リプロファイリング リミテッド
Publication of JP2017514816A publication Critical patent/JP2017514816A/ja
Publication of JP2017514816A5 publication Critical patent/JP2017514816A5/ja
Application granted granted Critical
Publication of JP6730194B2 publication Critical patent/JP6730194B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2016564185A 2014-05-09 2015-05-11 アンドロゲン合成モジュレーター Active JP6730194B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461990800P 2014-05-09 2014-05-09
US61/990,800 2014-05-09
PCT/EP2015/060388 WO2015169971A1 (en) 2014-05-09 2015-05-11 Modulators of androgen synthesis

Publications (3)

Publication Number Publication Date
JP2017514816A JP2017514816A (ja) 2017-06-08
JP2017514816A5 JP2017514816A5 (enExample) 2018-09-06
JP6730194B2 true JP6730194B2 (ja) 2020-07-29

Family

ID=53269444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016564185A Active JP6730194B2 (ja) 2014-05-09 2015-05-11 アンドロゲン合成モジュレーター

Country Status (8)

Country Link
EP (1) EP3139923B1 (enExample)
JP (1) JP6730194B2 (enExample)
CN (1) CN106456644B (enExample)
AU (3) AU2015257594A1 (enExample)
CA (1) CA2950800C (enExample)
ES (1) ES2970762T3 (enExample)
NZ (1) NZ726050A (enExample)
WO (1) WO2015169971A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1211868A1 (en) 2012-09-26 2016-06-03 Tangent Reprofiling Limited Modulators of androgen synthesis
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
SG11201906735RA (en) 2017-01-23 2019-08-27 Regeneron Pharma Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
JP2020516283A (ja) 2017-04-11 2020-06-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒドロキシステロイド（１７−ベータ）デヒドロゲナーゼ（ｈｓｄ１７ｂ）ファミリーのメンバーのモジュレーターの活性をスクリーニングするためのアッセイ
KR20240125690A (ko) 2017-10-11 2024-08-19 리제너론 파마슈티칼스 인코포레이티드 Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해
CN112020556A (zh) 2018-03-21 2020-12-01 瑞泽恩制药公司 第13型17β羟基类固醇脱氢酶(HSD17B13)iRNA组成物及其使用方法
US11957687B2 (en) 2019-07-02 2024-04-16 Regeneron Pharmaceuticals, Inc. Modulators of HSD17B13 and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319950B1 (en) * 1997-02-18 2001-11-20 Michael C. Seidel Suppression of carcinoma using high purity conjugated linoleic acid (CLA)
AU2002231190B2 (en) * 2000-12-23 2005-11-03 Creighton University Methods for inducing apoptosis and inhibiting proliferation in cancer cells
EP1626703A2 (en) * 2003-05-22 2006-02-22 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells
WO2012129673A1 (en) * 2011-03-25 2012-10-04 Universite Laval INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10
HK1211868A1 (en) * 2012-09-26 2016-06-03 Tangent Reprofiling Limited Modulators of androgen synthesis
US9375433B2 (en) * 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis

Also Published As

Publication number Publication date
JP2017514816A (ja) 2017-06-08
CN106456644B (zh) 2021-06-15
CN106456644A (zh) 2017-02-22
WO2015169971A1 (en) 2015-11-12
NZ726050A (en) 2018-04-27
CA2950800C (en) 2023-01-10
CA2950800A1 (en) 2015-11-12
AU2018203135A1 (en) 2018-05-24
AU2019279922A1 (en) 2020-01-16
ES2970762T3 (es) 2024-05-30
EP3139923A1 (en) 2017-03-15
EP3139923B1 (en) 2023-09-27
AU2015257594A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
JP6734346B2 (ja) アンドロゲン合成モジュレーター
US10111877B2 (en) Modulators of androgen synthesis
EP3139923B1 (en) Composition for treating pancreatic adenocarcinoma
JP2017514816A5 (enExample)
JP2019077727A (ja) 癌の処置のための組成物
RU2009113615A (ru) Ингибитор киназы
KR20230084163A (ko) 항체-약물 접합체와 parp1 선택적 억제제의 조합
CN102770129A (zh) 治疗癌症的方法和组合物
AU2017207291A1 (en) Methods for the treatment of myeloid derived suppressor cells related disorders
CA3225305A1 (en) Compositions and methods for inhibiting creatine transport as a treatment for cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180718

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200507

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200702

R150 Certificate of patent or registration of utility model

Ref document number: 6730194

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250